Automated Biochemical Analyzers Market to Reach $24.1 Billion, Globally, by 2033 at 12.2% CAGR: Allied Market Research
September 19, 2024 06:42 ET | Allied Analytics LLP
Wilmington, Delaware, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Automated Biochemical Analyzers Market by Analyzer (Biochemistry Analyzers, Immuno-Based...
22157.jpg
Global Drug Safety & Pharmacovigilance Certification Program Regulatory Requirements Webinar (ON-DEMAND)
September 18, 2024 11:13 ET | Research and Markets
Dublin, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The "Global Regulatory Requirements for Drug Safety & Pharmacovigilance Certification Program" training has been added to ResearchAndMarkets.com's...
Transparency Market Research
Erythropoietin Drugs Market Estimated to Reach USD 14.3 billion, Advancing at a CAGR of 3.8% by 2034: Transparency Market Research Inc.
September 18, 2024 07:05 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 18, 2024 (GLOBE NEWSWIRE) -- The global erythropoietin drugs market is estimated to surge at a CAGR of 3.8% from 2024...
Nader Sanai, MD
Ivy Brain Tumor Center’s Dr. Nader Sanai Named Arizona Bioscience Researcher of the Year
September 17, 2024 11:00 ET | Ivy Brain Tumor Center
Phoenix, AZ, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, Chief of Neurosurgical Oncology at Barrow Neurological Institute, and the Francis &...
Logo (500 x 500 px) transparent background.png
PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease
September 16, 2024 04:00 ET | C4X Discovery Holdings PLC
C4X Discovery Holdings Limited PatientSeek identifies a genetic signature that separates a4b7 integrin therapy responder and non-responder populations in inflammatory bowel disease Progresses...
20231207IGIGlenmarkideantity™_SKHoriColourWBL.png
IGI Announces Publication in Nature Cancer on ISB 2001, IGI's Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma
September 11, 2024 05:00 ET | Ichnos Glenmark Innovation
Preclinical data in Nature Cancer showed IGI's ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity
approved logo.JPG
CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer
September 10, 2024 07:00 ET | Charm Therapeutics
PRESS RELEASE CHARM Therapeutics appoints Dr Beverley Carr as Chief Business Officer Highly experienced dealmaker to lead CHARM’s business development and drive strategic value from CHARM’s...
Superluminal Medicines Logo.jpg
Superluminal Medicines Closes $120 Million Series A Round
September 09, 2024 07:00 ET | Superluminal Medicines Inc.
Superluminal Medicines, Inc. announced the closing of a $120 million Series A funding round.
22157.jpg
2 Day Virtual Workshop: Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course
September 06, 2024 06:42 ET | Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Human Factors and Usability Engineering in the Development of Drug Delivery Products Training Course 24" conference has been added to ...
Leapfrog Logo.png
Leapfrog Bio Announces Publication in Nature PJ Precision Oncology Validating its Proprietary Precision PGx Platform™
September 05, 2024 07:00 ET | Leapfrog Bio
Leapfrog Bio today announced a publication in Nature PJ Precision Oncology describing and validating its Precision PGx Platform™